Analysts’ Recent Ratings Changes for Astrana Health (ASTH)

A number of research firms have changed their ratings and price targets for Astrana Health (NASDAQ: ASTH):

• 11/11/2025 – Astrana Health was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.
• 11/10/2025 – Astrana Health was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 11/10/2025 – Astrana Health had its price target lowered by analysts at TD Cowen from $40.00 to $35.00. They now have a “buy” rating on the stock.
• 11/7/2025 – Astrana Health had its price target lowered by analysts at BTIG Research from $50.00 to $45.00. They now have a “buy” rating on the stock.
• 10/10/2025 – Astrana Health was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
• 10/8/2025 – Astrana Health had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Astrana Health had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.